US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
Generic net sales of $1.42 billion reflect strong growth from new product launch performances in Developed Markets, continued growth from complex products, and solid performance across the broader European portfolio.On Thursday, Viatris Inc. (NASDAQ:VTRS) reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
周四，Viatris Inc.（纳斯达克：VTRS）报告了第二季度收入为3797万美元，略高于3777万美元的共识，在剥离调整后的运营基础上增长约2％。
Brands net sales reached $2.36 billion, reflecting strong growth in Greater China and the expansion of the company's portfolio in Emerging Markets and JANZ, partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia.
品牌净销售额达到23.6亿美元，反映了大中华地区的强劲增长和公司在新兴市场、JANZ领域的产品组合扩张，部分抵消了北美渠道动态不利和日本、澳洲政府价格监管的影响。
Related: Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs.
相关信息：诺华和维阿特斯因非法使用用于治疗癌症药物的HeLa细胞而被起诉。
Generic net sales of $1.42 billion reflect strong growth from new product launch performances in Developed Markets, continued growth from complex products, and solid performance across the broader European portfolio.
通用药净销售额达到14.2亿美元，反映了发达市场新产品推出表现强劲、复杂产品持续增长以及整个欧洲产品组合表现出色。
The company generated approximately $210 million in new product revenues, primarily driven by Breyna, lisdexamfetamine, and other new products globally.
公司产生了约2,100万美元的新产品收入，主要由Breyna、左旋甲基苯丙胺和其他全球新产品推动。
The company reported adjusted EPS of $0.69, down 8% year over year, beating the consensus of $0.68.
公司报告调整后的每股收益为0.69美元，同比下降8%，超过预期，预期为0.68美元。
"I am pleased to report strong second quarter results in which we delivered divestiture-adjusted operational revenue growth across all segments, including strong growth in Greater China. This represents our fifth consecutive quarter of divestiture-adjusted operational revenue growth and demonstrates our ability to execute and grow our base business," said Scott Smith, CEO.
“我很高兴地报告我们在第二季度实现了强劲的业绩，所有业务板块均实现了摘牌调整后运营收入的增长，包括大中华区强劲增长。这是我们连续第五个季度实现摘牌调整后的运营收入增长，证明了我们的执行能力和基础业务增长能力，”首席执行官Scott Smith表示。
Guidance: Viatris says strong year-to-date performance gives it confidence in raising its outlook to approximately $500 million to $600 million in new product revenues in 2024 from prior range of $450 million to $550 million.
引导方针：维阿特斯表示，强劲的年初至今表现使其有信心将2024年的新产品收入展望提高到约5亿至6亿美元，之前的展望为4.5亿至5.5亿美元。
Viatris expects 2024 sales of $14.6 billion – $15.1 billion versus the prior guidance of $14.98 billion – $15.48 billion and consensus of $14.956 billion.
维阿特斯预计2024年销售额为146亿至151亿美元，而之前的展望为149.8亿至154.8亿美元，共识为149.56亿美元。
The company expects 2024 adjusted EPS of $2.58 – $2.73, versus the prior guidance of $2.66 – $2.81 and the consensus of $2.73.
该公司预计2024年调整后的每股收益为2.58美元至2.73美元，而之前的展望为2.66美元至2.81美元，共识为2.73美元。
Price Action: VTRS stock is up 5.33% at $11.97 at last check Thursday.
股票价格行动：截至星期四最后一次检查，VTRS股价上涨5.33%，至11.97美元。
Illustration of Phrama lab worker created with MidJourney.
药厂实验室工作者插图，由MidJourney创建。
- GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges.
- GoodRx报告第二季度业绩，处方收入增加，但订阅方面存在挑战。
